Myasthenia Gravis (MG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Myasthenia Gravis (MG) Market Outlook
Thelansis’s “Myasthenia Gravis (MG)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Myasthenia Gravis (MG) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Myasthenia
Gravis (MG) Overview
Myasthenia
Gravis (MG) is an autoimmune disease characterized by muscle weakness and
fatigue. It is a B-cell mediated condition, with antibodies targeting the
acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related
protein 4 (LRP4), or the postsynaptic membrane at the neuromuscular junction.
Auto-antibodies against the acetylcholine receptor (AChR), muscle-specific
kinase, and lipoprotein-related protein four are well-established diagnostic
markers and pathogenic factors. These auto-antibodies play a crucial role in
classifying Myasthenia Gravis patients into subgroups. Fortunately, modern
treatments offer a positive prognosis for MG patients, including
immunosuppression, symptom management, and support. Most individuals with mild
to moderate symptoms achieve complete remission or significant improvement. MG
can be categorized into five types: congenital myasthenia gravis, generalized
myasthenia gravis, ocular myasthenia gravis, transient neonatal myasthenia
gravis, and juvenile myasthenia gravis, based on disease onset timing,
neuromuscular dysfunction cause, and affected muscle groups.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment